Y-mAbs Therapeutics price target lowered to $25 from $26 at BMO Capital

BMO Capital lowered the firm’s price target on Y-mAbs Therapeutics to $25 from $26 but keeps an Outperform rating on the shares. BMO cites the company’s below-consensus revenue and reduced FY24 outlook, though the firm’s view on Danyelza’s growth and ability to continue to fund the company’s differentiated SADA radiopharmaceutical platform are unchanged, the analyst tells investors in a research note. BMO also believes that Y-mAbs’ SADA technology platform that has the potential to “transform the application of radioimmunotherapy in oncology”.